You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

HIV & Aging

In this presentation, Dr. Andrew Clark, Global Medical Lead with ViiV Healthcare, highlights a number of relevant clinical and psychosocial aspects related to HIV and aging, and the management of people living with HIV who are over the age of 50.

Presented by Dr. Andrew Clark, Global Medical Lead, ViiV Healthcare.

TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40kg.

Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.

TIVICAY is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults, adolescents and children aged 6 years and over, weighing at least 15kg.

Triumeq

(dolutegravir/abacavir/lamivudine)

Product information

Prescribing information

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.